BOTHELL, Wash.--(BUSINESS WIRE)--EKOS Corporation announced today the EKOS EkoSonic ® Endovascular System is the first endovascular device approved for the treatment of pulmonary embolism (PE). The ...

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ -- Data ...

Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs.

Responding to a recently released American College of Chest Physicians evidence-based clinical practice guidelines for antithrombotic and thrombolytic therapy (.pdf), EKOS® Corporation from Bothell, ...

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices Each year, approximately 350,000 patients in the United ...

Data from patients treated with the EKOS system also demonstrated a lower rate of cardiorespiratory decompensation or collapse (3.7% vs. 10.3%), in which inability of the heart to maintain adequate ...

BOTHELL, Wash.-- EKOS Corporation announced today the EKOS EkoSonic® Endovascular System is the first endovascular device approved for the treatment of pulmonary embolism (PE). The EkoSonic® System, ...

HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism PR Newswire MARLBOROUGH, Mass. and NEW ORLEANS, March ...